ACRF Image X Institute

ACRF Image X Institute logo


The ACRF Image X Institute is a world-leading centre for basic and translational medical innovation. Our work focuses on radiation oncology imaging and targeted radiotherapy systems.

The ACRF Image X Institute provides a site and forum where academia, medicine, industry and government can advance the science and clinical practice of cancer treatment.

We welcome researchers from around the world to visit our institute. Come to present your work, collaborate or participate in training and development. To find out about how you can get involved, visit our Opportunities page.

ACRF Image X Institute Group

TWITTER FEED

LATEST NEWS


AAPM 2018 - Congratulations to our largest cohort yet!

AAPM Cohort 2018

AAPM Cohort, 2018

August 8, 2018

Our researchers have returned from the 60th annual American Association of Physics in Medicine (AAPM) meeting held this year in Nashville, Tennessee. This was the largest cohort of invited speakers we’ve had for the conference to date, with many researchers featured in the ‘science highlights’ section of the conference. Two ‘Best In Physics’ titles were awarded to Dr Tess Reynolds and Dr Brendan Whelan.

The conference gave opportunities for us to strengthen bonds with other researchers, as well as industry partners and vendors.

We congratulate our team for their outstanding presentations, a testament to the hard work they put in.

University of Sydney Principal Research Fellowship awarded to Ricky O'Brien

Ricky O

Ricky O'Brien at the Hybrid Theatre. Photo by Julia Johnson.

July 19, 2018

We're thrilled that through a competitive process Associate Professor Ricky O'Brien has been awarded a University of Sydney Principal Research Fellowship. This award recognises the outstanding work that Ricky has done and will continue to do in to the future.

Real-time image-guided adaptive radiation therapy on a standard linear accelerator

29 March 2018

Tumours move during radiotherapy treatment, reducing the geometric and dosmetric accuracy of the treatment. Typically, imaging is performed before the treatment for planning purposes, but the motion of the tumour is not monitored during treatment delivery. We developed a method that reconstructs the images obtained by onboard imaging systems found in most linear accelerators to monitor the position of the tumour during treatment - Kilovoltage Intrafraction Monitoring (KIM). We recently reported that prostate motion estimated with KIM correlates well with the true motion. KIM is used in the TROG 15.01 SPARK trial to monitor target motion in prostate cancer patients so treatment delivery can be suspended if motion exceeds a threshold, and the patient can be repositioned. The LARK trial is about to commence using KIM to monitor liver tumour motion.

Another technology we developed has also recently been tested in a clinical trial of prostate cancer radiotherapy treatment. The multileaf collimator (MLC) is found on most linear accelerators and shapes the radiation beam. We developed software to control the MLC during treatment delivery and adapt the beam to the motion of the prostate. This improved the accuracy of the radiotherapy treatment. In this trial, tumour motion was monitored using the Calypso System - an electromagnetic-based monitoring system that is not available for the majority of radiotherapy patients.

To adapt the radiation beam to track the target on a standard radiotherapy system, we have combined our technologies, using KIM to monitor motion and beam adaptation via the MLC to adapt the radiation beam to the motion. This enables radiotherapy to be guided by images obtained during treatment with a standard linear accelerator. Our first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator has recently been published and is featured in the MedicalPhysicsWeb News. The integration of these technologies with existing radiotherapy systems would allow beam adaptation during treatment to be accessible for the majority of radiotherapy patients.